Safety and Tolerability of Donepezil at Doses up to 20 mg/dayResults from a Pilot Study in Patients with Alzheimer’s Disease

被引：0
|
作者：
Rachelle S. Doody
Jody Corey-Bloom
Richard Zhang
Honglan Li
John Ieni
Rachel Schindler
机构：
[1] Baylor College of Medicine,Alzheimer’s Disease and Memory Disorders Center
[2] UCSD School of Medicine,Department of Neurosciences
[3] Pfizer Inc.,undefined
[4] Eisai Inc.,undefined
来源：
Drugs & Aging | 2008年 / 25卷
关键词：
Rivastigmine; Galantamine; Last Observation Carry Forward; Psychometric Measure; Adverse Event Monitoring;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Donepezil is licensed for the treatment of mild-to-moderate Alzheimer’s disease (AD) at doses of 5–10 mg/day and has recently been approved in the US for severe AD. Multiple studies have suggested that donepezil 10 mg/day provides additional cognitive and functional benefits over the 5 mg/day dose. Higher doses of donepezil, if safe and well tolerated, might provide further benefits for patients with AD.
引用
收藏
页码：163 / 174
页数：11
相关论文
共 50 条
  • [1] Safety and tolerability of donepezil at doses up to 20 mg/day - Results from a pilot study in patients with Alzheimer's disease
    Doody, Rachelle S.
    Corey-Bloom, Jody
    Zhang, Richard
    Li, Honglan
    Ieni, John
    Schindler, Rachel
    [J]. DRUGS & AGING, 2008, 25 (02) : 163 - 174
  • [2] The safety and tolerability of donepezil in patients with Alzheimer's disease
    Jackson, S
    Ham, RJ
    Wilkinson, D
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 : 1 - 8
  • [3] Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day
    Schindler, R
    Zhang, R
    Ieni, JR
    Li, H
    [J]. NEUROBIOLOGY OF AGING, 2004, 25 : S195 - S196
  • [4] Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day
    Schindler, R.
    Corey-Bloom, J.
    Doody, R.
    Zhang, R.
    Ieni, J. R.
    Li, H.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 44 - 45
  • [5] Safety and tolerability of high dose donepezil in patients with Alzheimer's disease: A preliminary report of a pilot study
    Shua-Haim, JR
    Pass, M
    Patel, S
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 356 - 357
  • [6] Donepezil: Tolerability and safety in Alzheimer's disease
    Pratt, RD
    Perdomo, CA
    Surick, IW
    Ieni, JR
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (09) : 710 - 717
  • [7] Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
    Farlow, Martin
    Veloso, Felix
    Moline, Margaret
    Yardley, Jane
    Brand-Schieber, Elimor
    Bibbiani, Francesco
    Zou, Heng
    Hsu, Timothy
    Satlin, Andrew
    [J]. BMC NEUROLOGY, 2011, 11
  • [8] Safety and tolerability of high dose donepezil in patients with Alzheimer's disease. A preliminary report of a pilot study
    Pass, MD
    Shua-Haim, JR
    Patel, S
    Patel, S
    Lee, P
    Patel, P
    Smith, J
    [J]. NEUROBIOLOGY OF AGING, 2004, 25 : S193 - S193
  • [9] Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
    Martin Farlow
    Felix Veloso
    Margaret Moline
    Jane Yardley
    Elimor Brand-Schieber
    Francesco Bibbiani
    Heng Zou
    Timothy Hsu
    Andrew Satlin
    [J]. BMC Neurology, 11
  • [10] Safety and tolerability of high dose donepezil in patients with Alzheimer's disease. A preliminary report of a pilot study.
    Shua-Haim, J
    Patel, S
    Patel, P
    Lee, P
    Pass, M
    Patel, S
    [J]. GERONTOLOGIST, 2004, 44 : 655 - 655
12345